Monday, 23 September 2019

Singapore firm to launch next-gen cancer study device

27 May 2014 | News | By BioSpectrum Bureau

Singapore: Singapore's emerging company Clearbridge BioMedics plans to launch its ClearCell FX System at American Society of Clinical Oncology (ASCO) to be held in Chicago from 30 May to 3 June 2014.

Clearbridge BioMedics' next-generation device is designed to isolate and capture circulating tumour cells (CTCs) from a blood sample, therefore, extending support to research and clinical studies to study cancer mortality. ClearCell FX System helps in understanding the genetic make-up of CTCs and would be instrumemtal in developing effective treatments for specific groups of patients.

"At Clearbridge BioMedics, we aim to bring clarity to cancer, by allowing each and every patient to benefit from timely, tailored treatment. Now that the system is commercially available for research purposes, we shall continue to move rapidly in getting the system ready for clinical diagnostics applications. Real-time monitoring of a patient's CTCs allows clinicians to develop the best treatment at the right time. By matching treatments to the patient, they benefit from optimal treatment outcomes, with fewer negative side-effects and lower costs," explained Mr Johnson Chen,
managing director, Clearbridge BioMedics.

With this launch, the ClearCell FX System would be available for cancer research applications for researchers to make new medical advances. It uses biomechanical properties to isolate CTCs.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls